Prof Stephen Hart

Photo

Personal Profile

Name: Stephen Hart Email: s.hart@ucl.ac.uk
Title: Prof Tel: 020 7905 2228
Department: ICH Genetics & Genomic Medicine Prog Fax: 020 7905 2810
Position: Professor of Epidemiology and Medical Statistics Address: Wolfson Centre for Gene Therapy of Childhood Disease, UCL In, 30 Guilford Str, London, WC1N 1EH
Research Domain: Basic Life Sciences, Cancer, Experimental Medicine, Infection, Immunology & Inflammation, Neuroscience, Personalised Medicine, Populations & Lifelong Health Web Page:  

Profile

Research Description

Gene therapy offers exciting opportunities for the development oftherapies in virtually all areas of medicine. Recent clinical advances arestarting to realise this potential although there remain many challenges amongst which delivery is a key issue. Much of my research has thereforefocused on this challenging area to develop delivery methods compatible withclinical use. In particular I have developed a family of synthetic gene delivery formulations, or nanoparticles, from conceptual stages through to treatment of disease models in vivo.  More recently we have extended our formulations to the delivery of siRNA and other oligonucleotides as well as imaging contrast agents and radiolabels for real-time imaging of delivery in vivo.

 I have established a number of collaborations, exploiting the breadth of high quality research groups at UCL, including Departments of Chemistry, Biochemical Engineering, Centre for Respiratory Medicine, and the Centre for Cardiovascular Biology and Medicine. These collaborations have led to highly productive interdisciplinary hypothesis-driven research, involving synthesis ofnovel reagents, studies to establish the fundamental rules and relationshipsconcerning vector structure and function and correction of animal models ofdisease.

Overall the research areas are non-viral vector development and gene therapy for: 1) gene therapy for cardiovascular diseases (bypass grafts), 2) gene therapy for respiratory diseases (cystic fibrosis), 3) gene therapy for cancer (neuroblastoma), 4) gene therapy for the brain, 5) further vector development.


Research Activities

Ciliopathies, cilia

Exploiting the principles of genetics to develop new molecular therapies for inherited and acquired diseases.

Quantitative approaches to investigate Cystic Fibrosis

Education Description

My teaching activity mainly concerns training of research students from MSc to PhD levels.

UCL Collaborators

Prof Peter Scambler; Dr Vivek Dua; Dr Paola Vergani; Prof David Selwood; Prof Philip Beales; Dr Robin Mcanulty; Prof Christopher O'callaghan; Dr Hannah Mitchison; Dr Eddie Chung; Dr Guy Moss

External Collaborators

Publications

    2014

    • Tagalakis AD, Lee DH, Bienemann AS, Zhou H, Munye MM, Saraiva L, McCarthy D, Du Z, Vink CA, Maeshima R, White EA, Gustafsson K, Hart SL (2014). Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery.. Biomaterials, , - . doi:10.1016/j.biomaterials.2014.06.003
    • Tagalakis AD, Jayarajan V, Bienemann AS, Lee DH, Zhou H, McCarthy D, Hart SL (2014). Anionic, Receptor-Targeted Nanocomplexes for Systemic and Neuronal Delivery of siRNA.

    2013

    • Munye MM, Smith CM, Hirst RA, Shoemark A, Delhove JM, Mckay TR, Hogg C, O'Callaghan C, Howe SJ, Hart SL (2013). Novel Human Bronchial Epithelial Cell Lines for the Study of Gene Therapy Approaches To Treat Primary Ciliary Dyskinesia.
    • Tagalakis AD, Kenny GD, Bienemann AS, McCarthy D, Munye MM, Taylor H, Wyatt ML, Lythgoe MF, White EA, Hart SL (2013). PEGylation improves the receptor-mediated transfection efficiency of peptide-targeted, self-assembling, anionic nanocomplexes.. J Control Release, , - . doi:10.1016/j.jconrel.2013.11.014
    • Kenny GD, Tagalakis AD, Hart SL, Lythgoe MF, Bienemann AS, Gill SS, White EA, Pugh JA, McLeod CW, Welser K, Campbell F, Tabor AB, Hailes HC (2013). Multifunctional receptor-targeted nanocomplexes for the delivery of therapeutic nucleic acids to the Brain. Biomaterials, 34(36), 9190 - 9200. doi:10.1016/j.biomaterials.2013.07.081
    • Tagalakis AD, Saraiva L, McCarthy D, Gustafsson KT, Hart SL (2013). Comparison of nanocomplexes with branched and linear peptides for siRNA delivery.. Biomacromolecules, 14(3), 761 - 770. doi:10.1021/bm301842j
    • Welser K, Campbell F, Kudsiova L, Mohammadi A, Dawson N, Hart SL, Barlow DJ, Hailes HC, Lawrence MJ, Tabor AB (2013). Gene delivery using ternary lipopolyplexes incorporating branched cationic peptides: the role of Peptide sequence and branching.. Mol Pharm, 10(1), 127 - 141. doi:10.1021/mp300187t
    • Meng Q, Irvine S, Tagalakis AD, McAnulty RJ, McEwan JR, Hart SL (2013). Inhibition of Neointimal Hyperplasia in a Rabbit Vein Graft Model Following Non-Viral Transfection with Human iNOS cDNA. Gene Therapy, , - .
    • Tagalakis AD, Kenny GD, Bienemann AS, Pugh JAT, Lythgoe MF, McLeod CW, White EA, Hart SL (2013). Anionic, Self-Assembling Nanocomplexes for Improved Receptor-Targeted Transfection In Vitro and In Vivo.
    • Manunta MDI, McAnulty RJ, McDowell A, Jin J, Ridout D, Fleming J, Bottoms SE, Tossici-Bolt L, Laurent GJ, Biassoni L, O'Callaghan C, Hart SL (2013). Airways Deposition of Nebulized Gene Delivery Nanocomplexes Monitored by Radioimaging Agents. Am J Respir Cell Mol Biol, 49(3), 471 - 480. doi:10.1165/rcmb.2013-0030OC

    2012

    • Tagalakis AD, Kenny G, Saraiva L, McCarthy D, Hart SL (2012). Development of Anionic Nanocomplexes for Targeted SiRNA and Plasmid DNA Delivery.
    • Writer MJ, Kyrtatos PG, Bienemann AS, Pugh JA, Lowe AS, Villegas-Llerena C, Kenny GD, White EA, Gill SS, McLeod CW, Lythgoe MF, Hart SL (2012). Lipid peptide nanocomplexes for gene delivery and magnetic resonance imaging in the brain.. J Control Release, 162(2), 340 - 348. doi:10.1016/j.jconrel.2012.07.002
    • Kenny GD, Villegas-Llerena C, Tagalakis AD, Campbell F, Welser K, Botta M, Tabor AB, Hailes HC, Lythgoe MF, Hart SL (2012). Multifunctional receptor-targeted nanocomplexes for magnetic resonance imaging and transfection of tumours.. Biomaterials, 33(29), 7241 - 7250. doi:10.1016/j.biomaterials.2012.06.042
    • Pugh JAT, Cox AG, McLeod CW, Bunch J, Writer MJ, Hart SL, Bienemann A, White E, Bell J (2012). Elemental imaging of MRI contrast agents: benchmarking of LA-ICP-MS to MRI. ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 403(6), 1641 - 1649. doi:10.1007/s00216-012-5973-z
    • Munye MM, Howe SJ, Hart SL (2012). Towards gene therapy for primary ciliary dyskinesia.
    • Tagalakis AD, Attwood M, Manunta MDI, Munye M, McAnulty RJ, Hart SL (2012). Targeted Nanocomplex-Delivered ENaC siRNA as a Therapeutic Strategy for Cystic Fibrosis.

    2011

    • Manunta MD, McAnulty RJ, Tagalakis AD, Bottoms SE, Campbell F, Hailes HC, Tabor AB, Laurent GJ, O'Callaghan C, Hart SL (2011). Nebulisation of receptor-targeted nanocomplexes for gene delivery to the airway epithelium.. PLoS One, 6(10), e26768 - . doi:10.1371/journal.pone.0026768
    • Manunta MDI, McAnulty RJ, Tagalakis AD, Bottoms SE, Campbell F, Hailes HC, Laurent GJ, O'Callaghan C, Hart SL (2011). Nebulisation of Receptor-Targeted Nanocomplexes for Gene Delivery to the Airway Epithelium. PLoS ONE, 6(10), - . doi:10.1371/journal.pone.0026768
    • Tagalakis AD, He L, Saraiva L, Gustafsson KT, Hart SL (2011). Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery.. Biomaterials, 32(26), 6302 - 6315. doi:10.1016/j.biomaterials.2011.05.022
    • Kwok A, Hart SL (2011). Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery.. Nanomedicine, 7(2), 210 - 219. doi:10.1016/j.nano.2010.07.005
    • Kwok A, Hart SL (2011). Comparative structural and functional studies of nanoparticle formulations for DNA and siRNA delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 7(2), 210 - 219. doi:10.1016/j.nano.2010.07.005
    • Tagalakis AD, He L, Saraiva L, Gustafsson KT, Hart SL (2011). Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials, 32(26), 6302 - 6315. doi:10.1016/j.biomaterials.2011.05.022
    • Tagalakis AD, Grosse SM, Meng QH, Mustapa MF, Kwok A, Salehi SE, Tabor AB, Hailes HC, Hart SL (2011). Integrin-targeted nanocomplexes for tumour specific delivery and therapy by systemic administration.. Biomaterials, 32(5), 1370 - 1376. doi:10.1016/j.biomaterials.2010.10.037
    • Kudsiova L, Ho J, Fridrich B, Harvey R, Keppler M, Ng T, Hart SL, Tabor AB, Hailes HC, Lawrence MJ (2011). Lipid chain geometry of C14 glycerol-based lipids: effect on lipoplex structure and transfection.. Mol Biosyst, 7(2), 422 - 436. doi:10.1039/c0mb00149j

    2010

    • Hart SL (2010). Multifunctional nanocomplexes for gene transfer and gene therapy.. Cell Biol Toxicol, 26(1), 69 - 81. doi:10.1007/s10565-009-9141-y
    • Grosse SM, Tagalakis AD, Mustapa MF, Elbs M, Meng QH, Mohammadi A, Tabor AB, Hailes HC, Hart SL (2010). Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers.. FASEB J, 24(7), 2301 - 2313. doi:10.1096/fj.09-144220

    2009

    • Mustapa MF, Grosse SM, Kudsiova L, Elbs M, Raiber EA, Wong JB, Brain AP, Armer HE, Warley A, Keppler M, Ng T, Lawrence MJ, Hart SL, Hailes HC, Tabor AB (2009). Stabilized Integrin-Targeting Ternary LPD (Lipopolyplex) Vectors for Gene Delivery Designed To Disassemble Within the Target Cell. Bioconjug.Chem., 20(3), 518 - 532. doi:10.1021/bc800450r

    2008

    • Pilkington-Miksa MA, Sarkar S, Writer MJ, Barker SE, Shamlou PA, Hart SL, Hailes HC, Tabor AB (2008). Synthesis of Bifunctional Integrin-Binding Peptides Containing PEG Spacers of Defined Length for Non-Viral Gene Delivery. European Journal of Organic Chemistry, (17), 2900 - 2914. doi:10.1002/ejoc.200701188
    • Irvine SA, Meng QH, Afzal F, Ho J, Wong JB, Hailes HC, Tabor AB, McEwan JR, Hart SL (2008). Receptor Targeted Nanocomplexes Optimised for Gene Transfer to Primary Vascular Cells and Explant Cultures of Rabbit Aorta.. Molecular Therapy, 16, 508 - 515. doi:10.1038/sj.mt.6300381
    • Tagalakis AD, McAnulty RJ, Devaney J, Bottoms SE, Wong JB, Elbs M, Writer MJ, Hailes HC, Tabor AB, O'Callaghan C, Jaffe A, Hart SL (2008). A Receptor-targeted Nanocomplex Vector System Optimized for Respiratory Gene Transfer. Molecular Therapy, 16, 907 - 915. doi:10.1038/mt.2008.38
    • Pilkington-Miksa MA, Sarkar S, Writer MJ, Barker SE, Shamlou PA, Hart SL, Hailes HC, Tabor AB (2008). Synthesis of bifunctional integrin-binding peptides containing PEG spacers of defined length for non-viral gene delivery. Eur J Org Chem, (17), 2900 - 2914. doi:10.1002/ejoc.200701188
    • Wong JB, Grosse S, Tabor AB, Hart SL, Hailes HC (2008). Acid Cleavable PEG lipids for Applications in a Ternary Gene Delivery Vector. Molecular Biosystems, 4(6), 532 - 541. doi:10.1039/b719782a
    • Hurley CA, Wong JB, Ho J, Writer M, Irvine SA, Lawrence MJ, Hart SL, Tabor AB, Hailes HC (2008). Mono- and dicationic short PEG and methylene dioxyalkylglycerols for use in synthetic gene delivery systems. Org.Biomol.Chem., 6(14), 2554 - 2559.

    2007

    • Barker SE, Grosse S, Siapati KE, Kritz A, Kinnon C, Thrasher AJ, Hart SL (2007). Immunotherapy for Neuroblastoma Delivered by Syngeneic Fibroblasts Transfected with IL-2 and IL-12.. British Journal of Cancer, 97(2), 210 - 217. doi:10.1038/sj.bjc.6603857
    • Barker SE, Grosse SM, Siapati EK, Kritz A, Kinnon C, Thrasher AJ, Hart SL (2007). Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12. Br J Cancer, 97(2), 210 - 217.
    • Hart SL, Grosse S, Tabor AB, Wong JB, Elbs M, Hailes HC, Mustapa MFM (2007). Preparation of Peptides and Lipids and their Complexes for the Delivery of Biologically Active Material to Cells.
    • Mustapa FM, Bell PC, Hurley CA, Nicol A, Guénin E, Sarkar S, Writer MJ, Barker SE, Wong JB, Pilkington-Miksa MA, Papahadjopoulos-Sternberg B, Shamlou PA, Hailes HC, Hart SL, Zicha D, Tabor AB (2007). Biophysical characterisation of an integrin-targeted lipopolyplex gene delivery vector. Biochemistry, 46(45), 12930 - 12944. doi:10.1021/bi701014y
    • Pilkington-Miksa MA, Writer MJ, Sarkar S, Meng QH, Barker SE, Shamlou PA, Hailes HC, Hart SL, Tabor AB (2007). Targeting Lipopolyplexes Using Bifunctional Peptides Incorporating Hydrophobic Spacer Amino Acids: Synthesis, Transfection and Biophysical Studies. Bioconjugate Chemistry, 18(6), 1800 - 1810. doi:10.1021/bc0700943
    • Mustapa MF, Bell PC, Hurley CA, Nicol A, Guénin E, Sarkar S, Writer MJ, Barker SE, Wong JB, Pilkington-Miksa MA, Papahadjopoulos-Sternberg B, Shamlou PA, Hailes HC, Hart SL, Zicha D, Tabor AB (2007). Biophysical characterization of an integrin-targeted lipopolyplex gene delivery vector.. Biochemistry, 46(45), 12930 - 12944. doi:10.1021/bi701014y

    2006

    • Writer M, Hurley CA, Sarkar S, Copeman DM, Wong JB, Odlyha M, Jayne Lawrence M, Tabor AB, McAnulty RJ, Ayazi Shamlou P, Hailes HC, Hart SL (2006). Analysis and optimization of the cationic lipid component of a lipid/peptide vector formulation for enhanced transfection in vitro and in vivo.. J Liposome Res, 16(4), 373 - 389. doi:10.1080/08982100600992500
    • Jaffe A, Prasad SA, Larcher V, Hart S (2006). Gene therapy for children with cystic fibrosis--who has the right to choose?. J Med Ethics, 32(6), 361 - 364.
    • Spencer H, Bonnet D, Siapati E, Hart S, Jaffe A (2006). Lack of lung engraftment following injection of human cord blood derived haemopoietic stem cells into irradiated NOC/SCID mice.
    • Writer M, Hurley CA, Sarkar S, Copeman DM, Wong JB, Odlyha M, Jayne LM, Tabor AB, McAnulty RJ, Ayazi SP, Hailes HC, Hart SL (2006). Analysis and optimization of the cationic lipid component of a lipid/peptide vector formulation for enhanced transfection in vitro and in vivo. J Liposome Res., 16(4), 373 - 389.
    • Salehi SE, Tagalakis A, Jaffe A, Hart SL (2006). Cell specificity and duration of transgene expression in gene therapy for cystic fibrosis.
    • Obasanjo-Blackshire K, Mesquita R, Jabr RI, Molkentin JD, Hart SL, Marber MS, Xia Y, Heads RJ (2006). Calcineurin regulates NFAT-dependent iNOS expression and protection of cardiomyocytes: Co-operation with Src tyrosine kinase. Cardiovasc Res, 71(4), 672 - 683. doi:10.1016/j.cardiores.2006.05.026
    • Meng QH, Jamal W, Hart SL, McEwan JR (2006). Application to vascular adventitia of a nonviral vector for TIMP-1 gene therapy to prevent intimal hyperplasia. Human Gene Therapy, 17(7), 717 - 727. doi:10.1089/hum.2006.17.717

    2005

    • Wong JB, Writer M, Irvine S, Tabor AB, Hart SL, Hailes HC (2005). Role of cationic lipids in a non-viral lipid/peptide/DNA (LID) delivery system.
    • Cui ZQ, Tuladhar R, Hart SL, Marber MS, Pearson JD, Baydoun AR (2005). Rate of transport of L-arginine is independent of the expression of inducible nitric oxide synthase in HEK 293 cells. Nitric Oxide, 12(1), 21 - 30.
    • Sarkar S, Lee LK, Hart SL, Hailes HC, Levy SM, Tabor A, Shamlou PA (2005). The fractal structure of polycation-DNA complexes. Biotechnology and Applied Biochemistry, 41(Pt 2), 127 - 136.
    • Hailes HC, Tabor AB, Wong JB, Pilkington-Miksa M, Hart SL, Hurley CA (2005). Preparation of Quaternary Ammonium Lipids and their Complexation with Peptides for Delivery to Cells.
    • Sarkar S, Lee LK, Hart SL, Hailes HC, Levy SM, Tabor AB, Azayi Shamlou P (2005). Fractal Structure of Polycation-DNA Complexes. Biotechnology and Applied Biochemistry, 41, 127 - 136.
    • Hart SL (2005). Lipid carriers for gene therapy.. Curr Drug Deliv, 2(4), 423 - 428.
    • Spencer H, Rampling D, Aurora P, Bonnet D, Hart SL, Jaffe A (2005). Transbronchial biopsies provide longitudinal evidence for epithelial chimerism in children following sex mismatched lung transplantation. Thorax, 60(1), 60 - 62.

    2004

    • Hart SL (2004). Synthetic vectors: Prospects and opportunities. The Journal of Gene Medicine, 6(9), 2 - .
    • Writer MJ, Marshall B, Pilkington-Miksa MA, Barker SE, Jacobsen M, Bell PC, Lester DH, Tabor AB, Hailes HC, Klein N, Hart SL (2004). Targeted Gene Delivery to Human Airway Epithelial Cells with Synthetic Vectors Incorporating Novel Targeting Peptides Selected by Phage Display. Journal of Drug Targeting, 12(4), 185 - 193.
    • Meng Q-H, Robinson D, Jenkins RG, McAnulty RJ, Hart SL (2004). Efficient transfection of non-proliferating human airway epithelial cells with a synthetic vector formulated with EGTA. The Journal of Gene Medicine, 6, 210 - 221.
    • Hodges RJ, Jenkins RG, Wheeler-Jones CPD, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, McAnulty RJ (2004). Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production.. American Journal Of Pathology, 165(5), 1663 - 1676.
    • Kritz AB, Writer M, Kinnon C, Hart SL (2004). Peptides from phage display libraries for targeted gene delivery via the p75 neurotrophic receptor (p75NTR). The Journal of Gene Medicine, 6(9), 22 - .
    • Spencer H, Rampling D, Aurora P, Bonnet D, Hart SL, Jaffe A (2004). Evidence for long-term epithelial engraftment in children following sex-mismatched lung transplantation.
    • Meng QH, Robinson D, Jenkins RG, McAnulty RJ, Hart SL (2004). Efficient transfection of non-proliferating human airway epithelial cells with a synthetic vector system.. The Journal of Gene Medicine, 6(2), 210 - 221.

    2003

    • Jenkins RG, Meng QH, Hodges RJ, Lee LK, Bottoms SE, Laurent GJ, Willis D, Ayazi Shamlou P, McAnulty RJ, Hart SL (2003). Formation of LID vector complexes in water alters physicochemical properties and enhances pulmonary gene expression in vivo.. Gene Therapy, 10(12), 1026 - 1034. doi:10.1038/sj.gt.3301963
    • Siapati KE, Barker S, Kinnon C, Michalski A, Anderson E, Brickell P, Thrasher AJ, Hart SL (2003). Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12.. British Journal of Cancer, 88(10), 1641 - 1648. doi:10.1038/sj.bjc.6600928
    • Sarkar S, Zhang H, Hart SL, Hailes HC, Tabor AB, Shamlou PA (2003). Prediction of Size Distribution of Lipid-peptide-DNA Vector Particles Using Monte Carlo Simulation Techniques. Biotechnology and Applied Biochemistry, 38, 95 - 102.
    • Jenkins RG, McAnulty RJ, Hart SL, Laurent GJ (2003). Pulmonary Gene Therapy. Realistic hope for the future, or false dawn in the promised land?. Monaldi Archives of Chest Disease, 59, 17 - 24.
    • Lee LK, Siapati EK, Jenkins RG, McAnulty RJ, Hart SL, Shamlou PA (2003). Biophysical characterization of an integrin-targeted non-viral vector. Medical Science Monitor, 9(1), BR54 - BR61.
    • Mistry A, Harbottle R, Hart S, Hodivala-Dilke KM (2003). Integrins and angiogenesis: unlocking the route to gene therapy. Current Opinion in Molecular Therapeutics, 5(6), 603 - 610.
    • Hsu C, Boysen MM, Gritton LD, Writer MJ, Devitt JPR, Hart SL, Von Seggern DJ (2003). Targeting of dendritic cells by pseudotyped and peptide-modified adenovirus vectors.
    • Pilkington-Miksa MA, Tabor AB, Hailes HC, Hart SL, Writer M, Shamlou PA, Sarkar S (2003). Synthesis of unusual integrin-binding peptides for inclusion into LID transfection complexes.
    • Sarkar S, Zhang H, Levy SM, Hart SL, Hailes HC, Tabor AB, Shamlou PA (2003). Prediction of size distribution of lipid-peptide-DNA vector particles using Monte Carlo simulation techniques. Biotechnol Appl Biol, 38, 95 - 102. doi:10.1042/BA20030073
    • Hart SL (2003). Large animal models: bridging the gap. Molecular Therapy, 8(4), 528 - 529.
    • White RE, Wade-Martins R, Hart SL, Frampton J, Huey B, Desai-Mehta A, Cerosaletti KM, Concannon P, James MR (2003). Functional delivery of large genomic DNA to human cells with a peptide-lipid vector. The Journal of Gene Medicine, 5(10), 883 - 892.
    • Sarkar S, Zhang H, Hart SL, Hailes HC, Tabor AB, Ayazi SP (2003). Prediction of size distribution of lipid-peptide-DNA vector partcles using Monte Carlo simulation techniques. Biotechnology and Applied Biochemistry, 38(95), 102 - .
    • Sarkar S, Zhang H, Levy MS, Hart SL, Hales HC, Tabor AB, Shamlou PA (2003). Prediction of size distribution of lipid-peptide DNA vector particles using Monte-Carlo simulation techniques. Biotechnology and Applied Biochemistry, 38, 95 - 102.
    • Jenkins RG, McAnulty RJ, Hart SL, Laurent GJ (2003). Pulmonary Gene Therapy. Realistic hope for the future, or false dawn in the promised land?. Monaldi Arch Chest Dis, 59(1), 21 - 28.
    • Hurley CA, Hailes HC, Tabor AB, Hart SL (2003). Complexes for the Delivery of Biologically-Active Material to Cells.
    • Pilkington-Miksa MA, Tabor AB, Hart SL, Hailes HC, Writer M, Shamlou PA, Sarkhar S (2003). Synthesis of Unusual Integrin-Binding Peptides for Inclusion into LID Transfection Complexes.
    • Sarkar S, Zhang H, Levy MS, Hart SL, Hailes HC, Tabor AB, Shamlou PA (2003). Impact of biophysical and chemical properties of non-viral vector formulation on cell transfection.
    • Writer MJ, Hsu C, Devitt J, Tabor AB, Kinnon C, Von Seggern D, Hart SL (2003). Increased efficiency of gene transfer into dendritic cells using phage display-derived peptides.
    • Uduehi A, Mailhos C, Truman H, Thrasher A, Kinnon C, Hart SL (2003). Enhancement of integrin-mediated transfection of haematopoietic cells with a synthetic vector system. Biotechnology and Applied Biochemistry, 38, 201 - 209.

    2002

    • Jenkins G, Hart SL, Hodges RJ, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ (2002). Cyclooxygenase-2 overexpression, using an integrin-targeted gene delivery system (the LID vector), inhibits fibroblast proliferation in vitro and leads to increased prostaglandin E(2) in the lung. Chest, 121(3 Supp), 102S - 104S.
    • Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A (2002). Effective gene transfer to solid tumours using different nonviral gene delivery techniques: electroporation, liposomes and integrin-targeted vector. The Journal of Gene Medicine, 4, 438 - 446.
    • Cunningham S, Meng QH, Klein N, McAnulty RJ, Hart SL (2002). Evaluation of a porcine model for pulmonary gene transfer using a novel synthetic vector. The Journal of Gene Medicine, 4(4), 438 - 446.
    • Parkes R, Meng QH, Elena SK, McEwan JR, Hart SL (2002). High efficiency transfection of porcine vascular cells in vitro with a synthetic vector system. The Journal of Gene Medicine, 4(3), 292 - 299.
    • Cemazar M, Sersa G, Wilson J, Tozer GM, Hart SL, Grosel A, Dachs GU (2002). Effective gene transfer to solid tumors using different nonviral gene delivery techniques: Electroporation, liposomes, and integrin-targeted vector. Cancer Gene Ther, 9(4), 399 - 406. doi:10.1038/sj/cgt/7700454

    2001

    • Guenin E, Tabor AB, Hurley CA, Hailes HC, Hart SL (2001). Synthesis of labelled peptides for the study of gene delivery system.
    • Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ (2001). Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. American Journal Of Pathology, 158(4), 1411 - 1422.
    • Estruch EJ, Hart SL, Kinnon C, Winchester BG (2001). Non-viral, integrin-mediated gene transfer into fibroblasts from patients with lysosomal storage diseases. The Journal of Gene Medicine, 3(5), 488 - 497.
    • Wright MJ, Wightman LM, Lilley C, De Alwis M, Hart SL, Miller A, Coffin RS, Thrasher A, Latchman DS, Marber MS (2001). In vivo myocardial gene transfer: optimization, evaluation and direct comparison of gene transfer vectors. Basic Research in Cardiology, 96(3), 227 - 236.
    • Hailes HC, Hurley CA, Tabor AB, Hart SL (2001). The Synthesis of Cationic Lipids: Investigations into non-viral Lipid/Peptide/DNA transfection vector.

    2000

    • Jenkins RG, Herrick SE, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ, Hart SL (2000). An integrin-targetted non-viral vector for pulmonary Gene Therapy. Gene Therapy, 7, 393 - 400.
    • Jenkins RG, Hart SL, Meng QH, Kinnon C, Laurent GJ, McAnulty RJ (2000). Optimising lid vector complex preparation leads to enhanced gene expression in the lung..
    • Hart SL (2000). Synthetic vectors for gene therapy. Expert Opinion on Therapeutic Patents, 10(2), 199 - 208.
    • Compton SH, Mecklenbeck S, Mejia JE, Hart SL, Rice M, Cervini R, Barrandon Y, Larin Z, Levy ER, Bruckner-Tuderman L, Hovnanian A (2000). Stable integration of large (> 100 kb) PAC constructs in HaCaT keratinocytes using an integrin-targeting peptide delivery system. Gene Ther, 7(18), 1600 - 1605.
    • Dachs GU, Coralli C, Hart SL, Tozer GM (2000). Gene delivery to hypoxic cells in vitro. Brit J Cancer, 83(5), 662 - 667.
    • Parkes RJ, Hart SL (2000). Adhesion molecules and gene transfer. Advanced Drug Delivery Reviews, 44(2-3), 135 - 152.

    1999

    • Harbottle RP, Cooper R, Hart SL, Ladhoff A, McKay T, Knight AM, Wagner E, Miller A, Coutelle C (1999). RGD-oligolysine: a prototype construct for integrin-mediated gene delivery. Human Gene Therapy, 9, 1037 - 1047.
    • Jenkins RG, Hart SL, Chambers RC, Herrick SE, Kinnon C, Laurent GJ, McAnulty RJ (1999). Enhanced gene delivery to the lung using a novel integrin mediated vector.
    • Hart S (1999). Use of adhesion molecules for gene delivery. Experimental Nephrology, 7, 193 - 199.
    • (1999). Integrin-mediated vectors for gene transfer and therapy. Current Opinion in Molecular Therapeutics, 1(2), 197 - 203.
    • Zhang X, De Alwis M, Hart SL, Fitzke FW, Inglis SC, Boursnell ME, Levinsky RJ, Kinnon C, Ali RR, Thrasher AJ (1999). High-titer recombinant adeno-associated virus production from replicating amplicons and herpes vectors deleted for glycoprotein H. Hum Gene Ther, 10(15), 2527 - 2537.

    1998

    • Arancibia CV, Hart SL, Oral HB, Larkin DFP, George AJT (1998). Gene transfer to the corneal endothelium: A potential for modulating allograft rejection.. FASEB Journal, 12(4), A310 - A310.
    • Hart SL, Arancibia-Cárcamo CV, Wolfert MA, Mailhos C, O'Reilly NJ, Ali RR, Coutelle C, George AJ, Harbottle RP, Knight AM, Larkin DF, Levinsky RJ, Seymour LW, Thrasher AJ, Kinnon C (1998). Lipid-mediated enhancement of transfection by a nonviral integrin-targeting vector.. Hum Gene Ther, 9(4), 575 - 585. doi:10.1089/hum.1998.9.4-575
    • Goldsack NR, Chambers RC, Blanc-Brude OP, Laurent GJ, McAnulty RJ, Hart SL, Kinnon C (1998). Integrin mediated uptake of antisense oligonucleotides to the PAR-1 thrombin receptor inhibits thrombin induced fibroblast proliferation. FASEB Journal, 12(4), - .
    • Harbottle RP, Cooper RG, Hart SL, Ladhoff A, McKay T, Knight AM, Wagner E, Miller AD, Coutelle C (1998). An RGD-oligolysine peptide: A prototype construct for integrin-mediated gene delivery. Hum Gene Ther, 9(7), 1037 - 1047.

    1997

    • Mistry AR, Falciola L, Monaco L, Tagliabue R, Acerbis G, Knight A, Harbottle RP, Soria M, Bianchi ME, Coutelle C, Hart SL (1997). Recombinant HMG1 protein produced in Pichia pastoris: A nonviral gene delivery agent. BioTechniques, 22, 718 - 729.
    • Hart SL, Collins L, Gustafsson K, Fabre JW (1997). Integrin-mediated transfection with peptides containing arginine-glycine-aspartic acid domains. Gene Ther, 4(11), 1225 - 1230.
    • Shewring L, Collins L, Lightman S, Hart S, Gustafsson K, Fabre JW (1997). A non-viral vector system for efficient gene transfer to corneal endothelial cells via membrane integrins. Transplantation, 64, 763 - 769.

    1994

    • Hart SL, Knight AM, Harbottle RP, Mistry A, Hunger HD, Cutler DF, Williamson R (1994). Cell binding and internalization by filamentous phage displaying a cyclic Arg-Gly-Asp-containing peptide.. J Biol Chem, 269(17), 12468 - 12474.
    • HART S, KNIGHT A, HARBOTTLE R, CUTLER D, WILLIAMSON R, COUTELLE C (1994). Filamentous phage for cell targeting and gene delivery. J Cell Biochem, , 225 - 225.

    1993

    • Alton EWFE, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM, Jeffrey PK, Geddes DM, Hart SL, Williamson R, Fasold KI, Miller AD, Dickinson P, Stevenson BJ, McLachlan G, Dorin JR (1993). Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nature Genetics, 5, 135 - 142.

    1992

    • Hart SL, Koch K, Woods DR (1992). Identification of indigo-related pigments produced by Escherichia coli containing a cloned Rhodococcus gene. J Gen Microbiol, 138, 211 - 216.
    • Hart SL, Woods DR (1992). Construction of an insertional-inactivation cloning vector for Escherichia coli using a Rhodococcus gene for indigo production. J Gen Microbiol, 138, 205 - 209.

    1990

    • Hart SL, Kirby R, Woods DR (1990). Structure of a Rhodococcus gene encoding pigment production in Escherichia coli. J Gen Microbiol, 136, 1357 - 1363.

    1989

    • Hill R, Hart SL, Illing N, Kirby R, Woods DR (1989). Cloning and expression of Rhodococcus genes encoding pigment production in Escherichia coli. J Gen Microbiol, 135(6), 1507 - 1513.

    1986

    • Hart SL, Lane AB, Jenkins T (1986). Partial adenosine deaminase deficiency: another family from southern Africa.. Hum Genet, 74(3), 307 - 312.

    1985

    • Walker AR, Dison E, Walker BF, Hart S, Jenkins T (1985). Dental caries and blood groups in South African blacks.. Community Dent Oral Epidemiol, 13(1), 42 - 43.